1. GOLD. Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2024.
2. Doğan N, Varol Y, Köktürk N, Aksay E, Alpaydın A, Çorbacıoğlu Ş. Guideline for the Management of COPD Exacerbations: Emergency Medicine Association of Turkey (EMAT) / Turkish
Thoracic Society (TTS) Clinical Practice Guideline Task Force. Turk J Emerg Med. 2021;21:137-76.
3. Sağlık İstatistikleri Yıllığı 2022. In: Müdürlüğü TCSBSBSG, editor. 2024.
4. Başyiğit İ, Yıldız F. KOAH Atak ve Tedavisi. In: Wilke Topçu A, Söyletir G, Doğanay M, editors. Enfeksiyon Hastalıkları ve Mikrobiyolojisi2017.
5. Papi A, Contoli M, Caramori G, Mallia P, Johnston SL. Models of infection and exacerbations in COPD. Curr Opin Pharmacol. 2007;7(3):259-65.
6. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786-96.
7. Lee JH. Exacerbation of COPD. In: Lee SD, editor. COPD: Heterogeneity and Personalized Treatment: Springer; 2017. p. 261-6.
8. MacLeod M, Papi A, Contoli M, Beghé B, Celli BR, Wedzicha JA, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease
impact. Respirology. 2021;26(6):532-51.
9. Sapey E, Stockley RA. COPD exacerbations . 2: aetiology. Thorax. 2006;61(3):250-8.
10. Bhatt SP, Agusti A, Bafadhel M, Christenson SA, Bon J, Donaldson GC, et al. Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir
Crit Care Med. 2023;208(10):1026-41.
11. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-38.
12. Kim J, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study.
BMC Pulm Med. 2013;13:51.
13. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913-21.
14. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J
Respir Crit Care Med. 2006;173(10):1114-21.
15. Han MK, Lazarus SC. COPD: Diagnosis and Management. In: Broaddus VC, editor. Murray & Nadel’s Textbook of Respiratory Medicine: Elsevier; 2021.
16. Türk Toraks Derneği Pulmoner Tromboembolizm Tanı ve Tedavi Uzlaşı Raporu. Türk Toraks Derneği; 2021.
17. Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome
Proposal. Am J Respir Crit Care Med. 2021;204(11):1251-8.
18. Drummond MB, Wise RA. Chapter 40: Course and Treatment of Chronic Obstructive Pulmonary Disease. In: Grippi MA, editor. Fishman’s Pulmonary Diseases and Disorders. 6. New York:
McGraw-Hill Education; 2023.
19. Hurst JR, Wedzicha JA. Chapter 43: Management of Exacerbations in Chronic Obstructive Pulmonary Disease. In: Spiro SG, Silvestri G, Agustí A, editors. Clinical Respiratory Medicine:
Elsevier; 2012.
20. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-46.
21. Bardsley G, Pilcher J, McKinstry S, Shirtcliffe P, Berry J, Fingleton J, et al. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised
controlled trial. BMC Pulm Med. 2018;18(1):157.
22. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med.
2003;348(26):2618-25.
23. Alía I, de la Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving
ventilatory support. Arch Intern Med. 2011;171(21):1939-46.
24. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled
trial. Lancet. 1999;354(9177):456-60.
25. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of
Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941-7.
26. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154(2 Pt
1):407-12.
27. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease:
the REDUCE randomized clinical trial. Jama. 2013;309(21):2223-31.
28. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study.
Chest. 2007;132(6):1741-7.
29. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a ran-
domized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48-55.
30. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev.
2006(2):Cd004403.
31. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised
controlled trial. Bmj. 2010;341:c5462.
32. Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and
end-expiratory lung volumes: a randomised crossover trial. Thorax. 2016;71(8):759-61.
33. Bruni A, Garofalo E, Cammarota G, Murabito P, Astuto M, Navalesi P, et al. High Flow Through Nasal Cannula in Stable and Exacerbated Chronic Obstructive Pulmonary Disease Patients.
Rev Recent Clin Trials. 2019;14(4):247-60.
34. Oczkowski S, Ergan B, Bos L, Chatwin M, Ferrer M, Gregoretti C, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. Eur Respir J. 2022;59(4).
35. Chandra D, Stamm JA, Taylor B, Ramos RM, Satterwhite L, Krishnan JA, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the
United States, 1998-2008. Am J Respir Crit Care Med. 2012;185(2):152-9.